Introduction: Bone disease associated with renal failure is termed renal osteodystrophy and is quite heterogeneous. Microscopic examination of a bone biopsy specimen is still considered the gold standard for diagnosis. Nevertheless, recent studies suggest that serum markers of bone formation and resorption may be of additional help in assessing bone turnover. Osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL) constitute a complex mediator system involved in the regulation of the resorption process in bone. The present work aimed at studying the serum levels of osteoprotegerin and relation of osteoprotegerin to PTH and x-ray features of renal osteodystrophy has been studied. Subjects and methods: The present study was conducted on three groups Group I: 20 patients with chronic kidney disease( CKD) divided into two subgroups: Group Ia: 10 patients in stage 2 CKD (GFR of 60-89 ml/min) and stage 3 CKD (GFR of 30-59 ml/min).Group Ib: 10 patients in stage 4 CKD (GFR of 15-29 ml/min) and stage 5 CKD (GFR of <15 ml/min).Group II: 20 patients on maintenance hemodialysis for more than one year They were divided into two subgroups: Group IIa: 10 patients with intact PTH < 300 pg/ml.Group IIb: 10 patients with intact PTH > 300 pg/ml.Group III:10 age and sex matched healthy controls.Investigations will include measurements of Serum calcium,phosphorus, serum alkaline phosphatase,serum intact PTHand Assay of serum osteoprotegerin by enzyme linked immunosorbent assay (ELISA) technique. Results: Serum levels of OPG were higher in patients with CKD and patients on maintenance hemodialysis than healthy control. Serum levels of OPG were significantly higher in stage 4 and 5 CKD than in stage 2 and 3 CKD. Conclusions: Serum OPG level could be of help in the non-invasive diagnosis and monitoring of bone turn over state in patients with CKD.
| Published in |
American Journal of Internal Medicine (Volume 4, Issue 2-1)
This article belongs to the Special Issue Different Medical Research From Middle East |
| DOI | 10.11648/j.ajim.s.2016040201.12 |
| Page(s) | 5-12 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Osteoprotegerin, uremic pateints, diagnosing, Bone Disease
| [1] | Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945 –53. |
| [2] | Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43:558– 65. |
| [3] | Malyszko J, Wolczynski S, Malyszko JS, et al. Correlations of new markers of bone formation and resorption in kidney transplant recipients. Transplant Proc 2003; 35:1351– 54. |
| [4] | Naurla A, Jairam A, Baliga V, et al. Pathogenesis and management of renal osteodystrophy. Ind J Nephrol 2007; 17: 147-88. |
| [5] | Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell1997; 89: 309–19. |
| [6] | Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun1998; 247: 610–615. |
| [7] | Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor‐κB ligand and osteoprotegerin in bone cell biology. J Mol Med2001; 79: 243– 53. |
| [8] | Wada T, Nakashima T, Hiroshi N. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12:17–25. |
| [9] | Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490– 95. |
| [10] | Whyte M, Obrecht S, Finnegan P, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347:175–84. |
| [11] | Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002; 11:2119–27. |
| [12] | Boyce B, Xing L, Chen D. Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. Cell Metab 2005; 2:344–45. |
| [13] | Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260– 68. |
| [14] | Bennett B, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoEmice. Arterioscler Thromb Vasc Biol 2006; 26:2117–24. |
| [15] | Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95:1046– 57. |
| [16] | Hass M, Leko-Mohr Z, Roschger P, et al. Osteoprotegerin and parathyroid hormone as markers of high turn-over osteodystrophy and decreased bone mineralization in haemodialysis patients. Am J Kidney Dis 2002; 39: 50-6. |
| [17] | Bervoetes A, Spasovski G, Behets G, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007. |
| [18] | Hruska K, Saaba G, Matheu S, et al. Renal osteodystrophy, phosphorus homeostasis, and vascular calcification. Semin Dial 2007; 20: 309-15. |
| [19] | Jarava C, Armas J, Salgueira M. Bone alkaline phosphatase in renal osteodystrophy. Nephrol Dial Transplant 1996; 11: 43-6. |
| [20] | Rogers A, Eastel R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90:6323–31. |
| [21] | Vattikuti R, Towler D. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004; 286 :686- 96. |
| [22] | Kazama J, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor ( osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39:525- 32. |
| [23] | Nessim I, Waked E, Madani H, et al. Evaluation of serum osteoprotegerin and fetuin A levels in Egyption patients with chronic kidney disease. Comp Clin Pathol 2011; 10: 128- 31. |
| [24] | Celic T, Josip S, Antun G, et al. Serum bone markers and coronaryartery calcification in end stage renal faliure patients and kidney transplant recipients. J Nephrol Therapeut 2012; 2:1-7. |
| [25] | Coen G, Paola B, Santo C. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplnt 2002; 17: 233-38. |
| [26] | Doumouchtsis K, Perra Desponia, Doumouchtsis Stergios, et al. Regulatory effect of parathyroid hormone on sRANKL-Osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial 2009; 13: 49- 55. |
| [27] | Doi S, Yorioka N, Masaki T, et al. Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. Ther Apher Dial 2004; 8:335–9. |
APA Style
Mohamed Magdy, Mona Mostafa, Heba Elshair, Hesham Elghoneimy. (2015). Study of Serum Osteoprotegerin Level in Uremic Patients and Its Relation to Renal Bone Disease. American Journal of Internal Medicine, 4(2-1), 5-12. https://doi.org/10.11648/j.ajim.s.2016040201.12
ACS Style
Mohamed Magdy; Mona Mostafa; Heba Elshair; Hesham Elghoneimy. Study of Serum Osteoprotegerin Level in Uremic Patients and Its Relation to Renal Bone Disease. Am. J. Intern. Med. 2015, 4(2-1), 5-12. doi: 10.11648/j.ajim.s.2016040201.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.s.2016040201.12,
author = {Mohamed Magdy and Mona Mostafa and Heba Elshair and Hesham Elghoneimy},
title = {Study of Serum Osteoprotegerin Level in Uremic Patients and Its Relation to Renal Bone Disease},
journal = {American Journal of Internal Medicine},
volume = {4},
number = {2-1},
pages = {5-12},
doi = {10.11648/j.ajim.s.2016040201.12},
url = {https://doi.org/10.11648/j.ajim.s.2016040201.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.s.2016040201.12},
abstract = {Introduction: Bone disease associated with renal failure is termed renal osteodystrophy and is quite heterogeneous. Microscopic examination of a bone biopsy specimen is still considered the gold standard for diagnosis. Nevertheless, recent studies suggest that serum markers of bone formation and resorption may be of additional help in assessing bone turnover. Osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL) constitute a complex mediator system involved in the regulation of the resorption process in bone. The present work aimed at studying the serum levels of osteoprotegerin and relation of osteoprotegerin to PTH and x-ray features of renal osteodystrophy has been studied. Subjects and methods: The present study was conducted on three groups Group I: 20 patients with chronic kidney disease( CKD) divided into two subgroups: Group Ia: 10 patients in stage 2 CKD (GFR of 60-89 ml/min) and stage 3 CKD (GFR of 30-59 ml/min).Group Ib: 10 patients in stage 4 CKD (GFR of 15-29 ml/min) and stage 5 CKD (GFR of Results: Serum levels of OPG were higher in patients with CKD and patients on maintenance hemodialysis than healthy control. Serum levels of OPG were significantly higher in stage 4 and 5 CKD than in stage 2 and 3 CKD. Conclusions: Serum OPG level could be of help in the non-invasive diagnosis and monitoring of bone turn over state in patients with CKD.},
year = {2015}
}
TY - JOUR T1 - Study of Serum Osteoprotegerin Level in Uremic Patients and Its Relation to Renal Bone Disease AU - Mohamed Magdy AU - Mona Mostafa AU - Heba Elshair AU - Hesham Elghoneimy Y1 - 2015/10/25 PY - 2015 N1 - https://doi.org/10.11648/j.ajim.s.2016040201.12 DO - 10.11648/j.ajim.s.2016040201.12 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 5 EP - 12 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.s.2016040201.12 AB - Introduction: Bone disease associated with renal failure is termed renal osteodystrophy and is quite heterogeneous. Microscopic examination of a bone biopsy specimen is still considered the gold standard for diagnosis. Nevertheless, recent studies suggest that serum markers of bone formation and resorption may be of additional help in assessing bone turnover. Osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL) constitute a complex mediator system involved in the regulation of the resorption process in bone. The present work aimed at studying the serum levels of osteoprotegerin and relation of osteoprotegerin to PTH and x-ray features of renal osteodystrophy has been studied. Subjects and methods: The present study was conducted on three groups Group I: 20 patients with chronic kidney disease( CKD) divided into two subgroups: Group Ia: 10 patients in stage 2 CKD (GFR of 60-89 ml/min) and stage 3 CKD (GFR of 30-59 ml/min).Group Ib: 10 patients in stage 4 CKD (GFR of 15-29 ml/min) and stage 5 CKD (GFR of Results: Serum levels of OPG were higher in patients with CKD and patients on maintenance hemodialysis than healthy control. Serum levels of OPG were significantly higher in stage 4 and 5 CKD than in stage 2 and 3 CKD. Conclusions: Serum OPG level could be of help in the non-invasive diagnosis and monitoring of bone turn over state in patients with CKD. VL - 4 IS - 2-1 ER -
Information
Email: